Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Many Mounjaro users are looking into alternative medications following news of a 170 percent price increase in the UK ...

WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss ...

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20%, according to a large, international study paid for by Novo Nordisk, the drugmaker behind the product.

A generic version of Wegovy is not currently available in the United States due to existing patents held by the manufacturer, Novo Nordisk, that may be active until 2041. When the U.S. patent for ...